Cognitive dysfunction in psychiatric disorders: Characteristics, causes and the quest for improved therapy

Nature Reviews Drug Discovery

Volumn 11, Issue 2, 2012, Pages 141-168

  Millan, Mark J ^a   Agid, Yves ^b   Brüne, Martin ^c   Bullmore, Edward T ^d   Carter, Cameron S ^e   Clayton, Nicola S ^f   Connor, Richard ^g   Davis, Sabrina ^h   Deakin, Bill ⁱ   Derubeis, Robert J ^j   Dubois, Bruno ^k   Geyer, Mark A ^l   Goodwin, Guy M ^m   Gorwood, Philip ⁿ   Jay, Thérèse M ⁿ   Joëls, Marian ^o   Mansuy, Isabelle M ^p   Meyer Lindenberg, Andreas ^q   Murphy, Declan ^r   Rolls, Edmund ^s   Saletu, Bernd ^t   Spedding, Michael ^a   Sweeney, John ^u   Whittington, Miles ^v   Young, Larry J ^w   more..

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UK   (United Kingdom)

^g UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

^h CNRS   (France)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF OXFORD   (United Kingdom)

ⁿ CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^o UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^p UNIVERSITY OF ZURICH   (Switzerland)

^q UNIVERSITY OF HEIDELBERG   (Germany)

^r KING'S COLLEGE LONDON   (United Kingdom)

^s UNIVERSITY OF WARWICK   (United Kingdom)

^t MEDICAL UNIVERSITY OF VIENNA   (Austria)

^u UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^v NEWCASTLE UNIVERSITY   (United Kingdom)

^w EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ACETYLCHOLINE; ADENOSINE A2 RECEPTOR ANTAGONIST; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BUNGAROTOXIN RECEPTOR; CALCINEURIN INHIBITOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CATECHOL METHYLTRANSFERASE INHIBITOR; CYTOKINE; DEXTRO AMINO ACID OXIDASE INHIBITOR; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; GLYCINE RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METABOTROPIC RECEPTOR ANTAGONIST; MUSCARINIC M1 RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; NORADRENALIN UPTAKE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; SEROTONIN 1A ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN 6 ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANXIETY; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; BRAIN FUNCTION; BRAIN REGION; CELL ACTIVITY; CELL DISRUPTION; CLINICAL FEATURE; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DECISION MAKING; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DOWN SYNDROME; DRUG TARGETING; ELECTROENCEPHALOGRAM; EPIGENETICS; EXECUTIVE FUNCTION; FRAGILE X SYNDROME; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; KORSAKOFF PSYCHOSIS; LANGUAGE PROCESSING; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MENTAL DISEASE; MENTAL PERFORMANCE; NARCOLEPSY; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROFIBROMATOSIS; NEUROPSYCHOLOGICAL TEST; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OCULOMOTOR SYSTEM; PANIC; PARKINSON DISEASE; PHOBIA; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY OF LIFE; REVIEW; RUBINSTEIN SYNDROME; SCHIZOPHRENIA; SENSORY GATING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL BEHAVIOR; SOCIAL COGNITION; SOCIAL INTERACTION; SOCIAL PHOBIA; STRESS; TIC; TRANSLATIONAL RESEARCH; TUBEROUS SCLEROSIS;

BRAIN; COGNITION; COGNITION DISORDERS; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PSYCHOMOTOR PERFORMANCE; RISK FACTORS; STRESS, PSYCHOLOGICAL;

EID: 84856472879     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3628     Document Type: Review

References (268)

1. Pessoa, L. On the relationship between emotion and cognition. Nature Rev. Neurosci. 9, 148-158 (2008).
2. Harmer, C. J. et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am. J. Psychiatry 166, 1178-1184 (2009).
3. Hill, S. K., Bichop, J. R., Palumbo, D. & Sweeney, J. A. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev. Neurother. 10, 43-57 (2010).
4. Millan, M. J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110, 135-370 (2006).
5. Dickinson, D. & Harvey, P. D. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr. Bull. 35, 403-414 (2009).
6. Kalkstein, S., Hurford, I. & Gur, R. C. Neurocognition in schizophrenia. Curr. Top. Behav. Neurosci. 4, 373-390 (2010).
7. Millan, M. J. in Animal and Translational Models for CNS Drug Discovery Vol. 1 (eds McArthur, R. A. & Borsini, F.) 1-57 (Academic Press, Burlington, Massachusetts, 2008).
8. Baron-Cohen, S. & Belmonte, M. K. Autism: a window onto the development of the social and the analytic brain. Annu. Rev. Neurosci. 28, 109-126 (2005). (Pubitemid 41098901)
9. Barnett, J. H. et al. Assessing cognitive function in clinical trials of schizophrenia. Neurosci. Biobehav. Rev. 34, 1161-1177 (2010).
10. Hauber, W. & Sommer, S. Prefrontostriatal circuitry regulates effort-related decision making. Cereb. Cortex 19, 2240-2247 (2009).
11. Kas, M. J. H. et al. Advances in multidisciplinary and cross-species approaches to examine the neurobiology of psychiatric disorders. Eur. Neuropsychopharmacol. 21, 532-544 (2011).
12. Burdick, K. E., Robinson, D. G., Malhotra, A. K. & Szeszko, P. R. Neurocognitive profile analysis in obsessive-compulsive disorder. J. Int. Neuropsychol. Soc. 14, 640-645 (2008). (Pubitemid 351935886)
13. McNally, R. J. Cognitive abnormalities in post-traumatic stress disorder. Trends Cogn. Sci. 10, 271-277 (2006). (Pubitemid 44183639)
14. Liberzon, I. & Sripada, C. S. The functional neuroanatomy of PTSD: a critical review. Prog. Brain Res. 167, 151-169 (2008).
15. Quirk, G. J. & Mueller, D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 33, 56-72 (2008). (Pubitemid 350191313)
16. Castaneda, A. E., Tuulio-Henriksson, A., Marttunen, M., Suvisaari, J. & Lönnqvist, J. A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. J. Affect. Disord. 106, 1-27 (2008). (Pubitemid 350309672)
17. Coles, M. E., Turks, C. L. & Heimberg, R. G. Memory bias for threat in generalized anxiety disorder: the potential importance of stimulus relevance. Cogn. Behav. Ther. 36, 65-73 (2007). (Pubitemid 47399172)
18. Gordeev, S. A. Cognitive functions and the state of nonspecific brain systems in panic disorders. Neurosci. Behav. Physiol. 38, 707-714 (2008).
19. Dere, E., Pause, B. M. & Pietrowsky, R. Emotion and episodic memory in neuropsychiatric disorders. Behav. Brain Res. 215, 162-171 (2010).
20. Brüne, M. Theory of mind in schizophrenia: a review of the literature. Schizophr. Bull. 31, 21-42 (2005). (Pubitemid 41214354)
21. Crow, T. J. The big bang theory of the origin of psychosis and the faculty of language. Schizophr. Res. 102, 31-52 (2008).
22. Galderisi, S. et al. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophr. Res. 115, 104-114 (2009).
23. Kurtz, M. M. & Gerraty, R. T. A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. Neuropsychology 23, 551-562 (2009).
24. Wolf, F., Brüne, M. & Assion, H. J. Theory of mind and neurocognitive functioning in patients with bipolar disorder. Bipolar Disord. 12, 657-666 (2010).
25. Zobel, I. et al. Theory of mind deficits in chronically depressed patients. Depress. Anxiety 27, 821-828 (2010).
26. Marazziti, D., Consoli, G., Picchetti, M., Carlini, M. & Faravelli, L. Cognitive impairment in major depression. Eur. J. Pharmacol. 626, 83-86 (2010).
27. Beevers, C. G., Clasen, P., Stice, E. & Schnyer, D. Depression symptoms and cognitive control of emotion cues: a functional magnetic resonance imaging study. Neuroscience 167, 97-103 (2010).
28. Vaidya, C. J. & Stollstorff, M. Cognitive neuroscience of attention deficit hyperactivity disorder: current status and working hypotheses. Dev. Disabil. Res. Rev. 14, 261-267 (2008).
29. Uekermann, J. et al. Social cognition in attention-deficit hyperactivity disorder (ADHD). Neurosci. Biobehav. Rev. 34, 734-743 (2010).
30. Sayin, A., Oral, N., Utku, C. Baysak, E. & Candansayar, S. Theory of mind in obsessive-compulsive disorder: comparison with healthy controls. Eur. Psychiatry 25, 116-122 (2010).
31. Hill, E. L. & Frith, U. Understanding autism: insights from mind and brain. Phil. Trans. R. Soc. Lond. B Biol. Sci. 358, 281-289 (2003). (Pubitemid 36257601)
32. Robinson, S., Goddard, L. Dritschel, B., Wisley, M. & Howlin, P. Executive functions in children with autism spectrum disorders. Brain Cogn. 71, 362-368 (2009).
33. Krause, J., Ruxton, G. D. & Krause, S. Swarm intelligence in animals and humans. Trends Ecol. Evol. 25, 28-34 (2010).
34. Adolphs, R. The social brain: neural basis of social knowledge. Annu. Rev. Psychol. 60, 693-716 (2009).
35. Fitch, W. T., Huber, L. & Bugnyar, T. Social cognition and the evolution of language: constructing cognitive phylogenies. Neuron 65, 795-814 (2010).
36. Gorwood, P., Corruble, E., Falissard, B. & Goodwin, G. M. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am. J. Psychiatry 165, 731-739 (2008). (Pubitemid 351810542)
37. Goodwin, G. M., Martinez-Aran, A., Glahn, D. C. & Vieta, E. Cognitive impairment in bipolar disorder: neurodevelopment of neurodegeneration? An ECNP expert meeting report. Eur. Neuropsychopharmacol. 18, 787-793 (2008).
38. Sarter, M., Parikh, V. & Howe, W. M. nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem. Pharmacol. 10, 658-667 (2009).
39. McAfoose, J. & Baune, B. T. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 33, 355-366 (2009).
40. Cunha, C., Brambilla, R. & Thomas, K. L. A simple role for BDNF in learning and memory? Front. Mol. Neurosci. 3, 1 (2010).
41. Robbins, T. W. & Arnsten, A. F. T. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu. Rev. Neurosci. 32, 267-287 (2009).
42. Lewis, D. A., Fish, K. N., Arion, D. & Gonzalez-Burgos, G. Perisomatic inhibition and cortical circuit dysfunction in schizophrenia. Curr. Neurobiol. 21, 866-872 (2011).
43. Lee, Y. S. & Silva, A. J. The molecular and cell biology of enhanced cognition. Nature Rev. Neurosci. 10, 126-140 (2009).
44. Neves, G., Cooke, S. F. & Bliss, T. V. P. Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nature Rev. Neurosci. 9, 65-75 (2008). (Pubitemid 350295694)
45. Collingridge, G. L., Peineau, S., Howland, J. G. & Wang, Y. T. Long-term depression in the CNS. Nature Rev. Neurosci. 11, 459-473 (2010).
46. Buzsaki, G. Neural syntax: cell assemblies, synapsembles, and readers. Neuron 68, 362-385 (2010).
47. Wang, X. J. Neurophysiological and computational principles of cortical rhythms in cognition. Physiol. Rev. 90, 1195-1268 (2010).
48. Bullmore, E. & Sporns, O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nature Rev. Neurosci. 10, 186-198 (2009).
49. Lynall, M. E. et al. Functional connectivity and brain networks in schizophrenia. J. Neurosci. 30, 9477-9487 (2010).
50. Gilmour, G. et al. NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 21 Mar 2011 (doi:10.1016/j.neuropharm.2011.03.015).
51. Heifets, B. D. & Castillo, P. E. Endocannabinoid signaling and long-term synaptic plasticity. Annu. Rev. Physiol. 71, 283-306 (2009).
52. Papaleo, F., Lipska, B. K. & Weinberger, D. R. Mouse models of genetic effects on cognition: relevance to schizophrenia. Neuropharmacology 5 May 2011 (doi:10.1016/j.neuropharm.2011.04.025).
53. McGuire, P., Howes, O. D., Stone, J. & Fusar-Poli, P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol. Sci. 29, 91-98 (2008).
54. Minzenberg, M. J. et al. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry 66, 811-822 (2009).
55. Pettersson-Yeo, W., Allen, P., Benetti, S., McGuire, P. & Mechelli, A. Dysconnectivity in schizophrenia: where are we now? Neurosci. Biobehav. Rev. 35, 1110-1124 (2011).
56. Li, X., Branch, C. A. & DeLisi, L. E. Language pathway abnormalities in schizophrenia: a review of fMRI and other imaging studies. Curr. Opin. Psychiatry 22, 131-139 (2009).
57. Knaus, T. A. et al. Language laterality in autism spectrum disorder and typical controls: a functional, volumetric, and diffusion tensor MRI study. Brain Lang. 112, 113-120 (2010).
58. Wass, S. Distortions and disconnections: disrupted brain connectivity in autism. Brain Cogn. 75, 18-28 (2011).
59. Kennedy, D. P. & Courchesne, E. The intrinsic functional organization of the brain is altered in autism. Neuroimage 39, 1877-1885 (2008).
60. Cubillo, A. & Rubia, K. Structural and functional brain imaging in adult attention-deficit/hyperactivity disorder. Expert Rev. Neurother. 10, 603-620 (2010).
61. Harrison, B. J. et al. Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch. Gen. Psychiatry 66, 1189-1200 (2009).
62. Van Marle, H. J. F., Hermans, E. J., Qin, S. & Fernandez, G. Enhanced resting-state connectivity of amygdala in the immediate aftermath of acute psychological stress. Neuroimage 53, 348-354 (2010).
63. Ehninger, D., Li, W., Fox, K., Stryker, M. P. & Silva, A. J. Reversing neurodevelopmental disorders in adults. Neuron 60, 950-960 (2008).
64. Belsky, J. et al. Vulnerability genes or plasticity genes? Mol. Psychiatry 14, 746-754 (2009).
65. Penrod, N. M., Cowper-Sallari, R. & Moore, J. H. Systems genetics for drug target discovery. Trends Pharmacol. Sci. 32, 623-630 (2011).
66. Liu, J. et al. Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Hum. Brain Mapp. 30, 241-255 (2009).
67. Jaaro-Peled, H. J. et al. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci. 32, 485-495 (2009).
68. Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M. & Steckler, T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34, 74-89 (2009).
69. Young, J. W., Powell. S. B., Risbrough, V., Marston, H. M. & Geyer, M. A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122, 150-202 (2009).
70. Balanzá-Martínez, V. et al. Neurocognitive endophenotypes (endophenocognotypes) from studies of relatives of bipolar disorder subjects: a systematic review. Neurosci. Biobehav. Rev. 32, 1426-1438 (2008).
71. Turetsky, B. I. et al. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 33, 64-94 (2007).
72. Walter, H. et al., Effects of a genome-wide supported psychosis risk variant on neural activation during a theory-of-mind task. Mol. Psychiatry 16, 462-470 (2011).
73. Mosconi, M. M. et al. Neurobehavioral abnormalities in first-degree relatives of individuals with autism. Arch. Gen. Psychiatry 67, 830-840 (2010).
74. Chamberlain, S. R. & Menzies, L. Endophenotypes of obsessive-compulsive disorder: rationale, evidence and future potential. Expert. Rev. Neurother. 9, 1133-1146 (2009).
75. Apud, J. A. & Weinberger, D. R. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 21, 535-557 (2007). (Pubitemid 46984856)
76. Roussos, P., Giakoumaki, S. G. & Bitsios, P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818C/G polymorphism. Biol. Psychiatry 66, 997-1004 (2009).
77. Bertolino, A. et al. Prefrontal-hippocampal coupling during memory processing is modulated by COMT Val158Met genotype. Biol. Psychiatry 60, 1250-1258 (2006). (Pubitemid 44693539)
78. Meyer-Lindenberg, A. et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J. Clin. Invest. 117, 672-682 (2007). (Pubitemid 46348525)
79. Esslinger, C. et al. Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage 54, 2514-2523 (2011).
80. Hashimoto, R. et al. The impact of a genome-wide supported psychosis variant in the ZNF804A gene on memory function in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 5, 153B, 1459-1464 (2010).
81. Karayiorgou, M., Simon, T. J. & Gogos, J. A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nature Rev. Neurosci. 11, 402-416 (2010).
82. Sigurdsson, T., Stark, K. L., Karayiorgou, M., Gogos, J. A. & Gordon, J. A. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 464, 763-767 (2010).
83. Joëls, M. & Baram, T. Z. The neuro-symphony of stress. Nature Rev. Neurosci. 10, 459-466 (2009).
84. Lupien, S. J., McEwen, B. S., Gunnar, M. R. & Heim, C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nature Rev. Neurosci. 10, 434-445 (2009).
85. Wang, X. D. et al. Forebrain CRF1 modulates early-life stress-programmed cognitive deficits. J. Neurosci. 21, 13625-13634 (2011).
86. Schwabe, L., Wolf, O. T. & Oitzl, M. S. Memory formation under stress: quantity and quality. Neurosci. Biobehav. Rev. 34, 584-591 (2010).
87. Howland, J. G. & Wang, Y. T. Synaptic plasticity in learning and memory: stress effects in the hippocampus. Prog. Brain Res. 169, 145-158 (2008). (Pubitemid 351451901)
88. Mailliet, F. et al. Protection of stress-induced impairment of hippocampal/prefrontal LTP through blockade of glucocorticoid receptors: implication of MEK signalling. Exp. Neurol. 211, 593-596 (2008).
89. Sandi, C. Glucocorticoids act on glutamatergic pathways to affect memory processes. Trends Neurosci. 34, 165-171 (2011).
90. Sotiropoulos, I. et al. Stress and glucocorticoid footprints in the brain-the path from depression to Alzheimer's disease. Neurosci. Biobehav. Rev. 32, 1161-1173 (2008).
91. Dorey, R. et al. Membrane mineralocorticoid but not glucocorticoid receptors of the dorsal hippocampus mediate the rapid effects of corticosterone on memory retrieval. Neuropsychopharmacology 36, 2639-2649 (2011).
92. Cerqueira, J. J., Maillet, F., Almeida, O. F., Jay, T. M. & Sousa, N. The prefrontal cortex as a key target of the maladaptive response to stress, J. Neurosci. 27, 2781-2787 (2007). (Pubitemid 46438976)
93. Holmes, A. & Wellman, C. L. Stress-induced prefrontal reorganization and executive dysfunction in rodents. Neurosci. Biobehav. Rev. 33, 773-783 (2009).
94. Roozendaal, B., McEwen, B. S. & Chattarji, S. Stress, memory and the amygdala. Nature Rev. Neurosci. 10, 423-433 (2009).
95. Oomen, C. A. et al. Early maternal deprivation affects dentate gyrus structure and emotional learning in adult female rats. Psychopharmacology 214, 249-260 (2011).
96. Champagne, D. L. et al. Maternal care and hippocampal plasticity: evidence for experience-dependent structural plasticity, altered synaptic functioning, and differential responsiveness to glucocorticoids and stress. J. Neurosci. 28, 6037-6045 (2008).
97. Millan, M. J. & Brocco, M. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimized D3 > D2 antagonist, S33138. Thérapie 63, 187-229 (2008).
98. Barch, D. M. Pharmacological strategies for enhancing cognition in schizophrenia. Curr. Top. Behav. Neurosci. 4, 43-96 (2010).
99. Margulies, C., Tully, T. & Dubnau, J. Deconstructing memory in Drosphila. Curr. Biol. 15, R700-R713 (2005).
100. Hawkins, R. D., Kandel, E. R. & Bailey, C. H. Molecular mechanisms of memory storage in Aplysia. Biol. Bull. 210, 174-191 (2006).
101. Champagne, D. L., Hoefnagels, C. C. M., de Kloet, R. E. & Richardson, M. K. Translating rodent behavioral repertoire to zebrafish (Danio rerio); relevance for stress research. Behav. Brain Res. 214, 332-342 (2010).
102. Emery, N. J. & Clayton, N. S. Comparative social cognition. Annu. Rev. Psychol. 60, 87-113 (2009).
103. Bolhuis, J. J., Okanoya, K. & Scharff, C. Twitter evolution: converging mechanisms in birdsong and human speech. Nature Rev. Neurosci. 11, 747-759 (2010).
104. Wallace, T., Ballard, T. M., Pouzet, B., Riedel, W. J. & Wettstein, J. G. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol. Biochem. Behav. 99, 130-145 (2011).
105. Levin, E. D., Bushnell, P. J. & Rezvani, A. H. Attention-modulating effects of cognitive enhancers. Pharmacol. Biochem. Behav. 99, 146-154 (2011).
106. Kaplan, G. B. & Moore, K. A. The use of cognitive enhancers in animal models of fear extinction. Pharmacol. Biochem. Behav. 99, 217-228 (2011).
107. Poe, G. R., Walsh, C. M. & Bjorness, T. E. Cognitive neuroscience of sleep. Prog. Brain Res. 185, 1-19 (2010).
108. Kyriacou, C. P. & Hastings, M. H. Circadian clocks: gene, sleep, and cognition. Trends Cogn. Sci. 14, 259-267 (2010).
109. Solas, M. et al. Interactions between age, stress and insulin on cognition: implications for Alzheimer's disease. Neuropsychopharmacology 35, 1664-1673 (2010).
110. El-Ghundi, M., O'Dowd, B. F. & George, S. R. Insights into the role of dopamine receptor systems in learning and memory. Rev. Neurosci. 18, 37-66 (2007).
111. Buchanan, R. W. et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol. Psychiatry 69, 442-449 (2010).
112. Graef, S., Schönknecht, P., Sabri, O. & Hegerl, U. Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology, 215, 205-229 (2011).
113. King, M. V., Marsden, C. A. & Fone, K. C. A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol. Sci. 29, 482-492 (2008).
114. Codony, X., Vela, J. M. & Ramirez, M. J. 5-HT6 receptors and cognition. Curr. Opin. Pharmacol. 11, 94-100 (2011).
115. Goodson, J. L. & Thompson, R. R. Nonapeptide mechanisms of social cognition, behavior and species-specific social systems Curr. Opin. Neurobiol. 20, 784-794 (2010).
116. Insel, T. R. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behaviour. Neuron 65, 768-779 (2010).
117. Meyer-Lindenberg, A., Domes, G., Kirsch, P. & Heinrichs, M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nature Rev. Neurosci. 12, 524-538 (2011).
118. Garnock-Jones, K. P. & Keating, G. M. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr. Drugs 11, 203-226 (2011).
119. Ramos, B. P. & Arnsten, A. F. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol. Ther. 113, 523-536 (2007). (Pubitemid 46365960)
120. Sallee, F. R. The role of α2-adrenergic agonists in attention-deficit/hyperactivity disorder. Postgrad. Med. 122, 78-87 (2010).
121. Liem-Moolenaar, M. et al. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. J. Psychopharmacol. 24, 1671-1679 (2010).
122. Saavedra-Velez, C., Yusim, A., Anbarasan, D. & Lindenmayer, J. P. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J. Clin. Psychiatry 70, 104-112 (2009).
123. Saletu, M. et al. Modafinil improves information processing speed and increases energetic resources for orientation of attention in narcoleptics: double-blind, placebo-controlled ERP studies with low-resolution brain electromagnetic tomography (LORETA). Sleep Med. 10, 850-858 (2009).
124. Uslaner, J. M. et al. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 57, 531-538 (2009).
125. Zhang, Z., Gong, N., Wang, W., Xu, L. & Xu, T. L. Bell-shaped d-serine actions on hippocampal long-term depression and spatial memory retrieval. Cereb. Cortex 18, 2391-2401 (2008).
126. Williams, G. V. & Castner, S. A. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience 139, 263-276 (2006).
127. Deng, W., Aimone, J. B. & Gage, F. H. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nature Rev. Neurosci. 11, 339-350 (2010).
128. Kasai, H., Fukuda, M., Watanabe, S., Hayashi-Takagi, A. & Noguchi, J. Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci. 33, 121-129 (2010).
129. Mansuy, I. M. & Shenolikar, S. Protein serine/threonine phosphatases in neuronal plasticity and disorders of learning and memory. Trends Neurosci. 29, 689-696 (2006).
130. Pertovaara, A., Haapalinna, A., Sirviö, J. & Virtanen, R. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective α2-adrenoceptor antagonist. CNS Drug Rev. 11, 273-288 (2005). (Pubitemid 43100465)
131. Lapiz, M. D. S. & Morilak, D. A. Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 137, 1039-1049 (2006). (Pubitemid 43053965)
132. Vellano, C. P., Lee, A. E., Dudek, S. M. & Hepler, J. R. RGS14 at the interface of hippocampal signaling and synaptic plasticity. Trends Pharmacol. Sci. 32, 666-674 (2011).
133. Vinkers, C. H. et al. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. Expert Opin. Investig. Drugs 19, 1217-1233 (2010).
134. Dφlen, G., Carpenter, R. L., Ocain, T. D. & Bear, M. F. Mechanism-based approaches to treating fragile X. Pharmacol. Ther. 127, 78-93 (2010).
135. Lascher, C. & Huber, K. M. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 65, 445-459 (2010).
136. Hoeffer, C. A. & Klann, E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 33, 67-75 (2010).
137. Franklin, T. & Mansuy, I. M. Epigenetic inheritance in mammals: evidence for the impact of adverse environmental effects. Neurobiol. Dis. 39, 61-65 (2010).
138. Day, J. J. & Sweatt, J. D. Epigenetic treatments for cognitive impairments. Neuropsychopharmacology 18 May 2011 (doi:10.1038/npp.2011.85).
139. Raddatz, R., Tao, M. & Hudkins, R. L. Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases. Curr. Top. Med. Chem. 10, 153-169 (2010).
140. Leiser, S. C., Bowlby, M. R., Comery, T. A. & Dunlop, J. A cog in cognition: how the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol. Ther. 122, 302-311 (2009).
141. Reneerkens, O. A. H., Rutten, K., Steinbusch, H. W. M., Blokland, A. & Prickaerts, J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 202, 419-443 (2009).
142. Schmidt, C. J. Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr. Top. Med. Chem. 10, 222-230 (2010).
143. Burgin, A. B. et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nature Biotech. 28, 63-70 (2010).
144. Sun, M. K. & Alkon, D. L. Pharmacology of protein kinase C activators: cognition-enhancing and antidementic therapeutics. Pharmacol. Ther. 127, 66-77 (2010).
145. Levallet, G., Hotte, M., Boulouard, M. & Dauphin, F. Increased particulate phosphodiesterase 4 in the prefrontal cortex supports 5-HT4 receptor-induced improvement of object recognition memory in the rat. Psychopharmacology 202, 125-139 (2009).
146. Puighemanal, E. et al. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nature Neurosci. 12, 1152-1158 (2009).
147. Gafford, G. M., Parsons, R. G. & Helmstette, F. J. Consolidation and reconsolidation of contextual fear memory requires mammalian target of rapamycin-dependent translation in the dorsal hippocampus. Neuroscience 182, 98-104 (2011).
148. Dewachter, I. et al. GSK3β, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at serine-9. Neurobiol. Dis. 35, 193-200 (2009).
149. Hooper, C. et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur. J. Neurosci. 25, 81-86 (2007). (Pubitemid 46096224)
150. Taglialatela, G., Hogan, D., Zhang, W. R. & Dineley, K. T. Intermediate-and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav. Brain Res. 200, 95-99 (2009).
151. Baumgδrtel, K. et al. Control of the establishment of aversive memory by calcineurin and Zif268. Nature Neurosci. 11, 572-578 (2009). (Pubitemid 351595207)
152. Pittenger, C. & Duman, R. S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33, 88-109 (2008). (Pubitemid 350191319)
153. Lacefield, C. O., Itskov, V., Reardon, T., Hen, R. & Gordon, J. A. Effects of adult-generated granule cells on coordinated network activity in the dentate gyrus. Hippocampus 29 Sep 2010 (doi:10.1002/hipo.20860).
154. Rolls, E. T. A computational theory of episodic memory formation in the hippocampus. Behav. Brain Res. 215, 180-196 (2010).
155. Wixted, J. T. & Squire, L. R. The medial temporal lobe and the attributes of memory. Trends Cogn. Sci. 15, 210-217 (2011).
156. Carolis, N. A. & Eisch, A. J. Hippocampal neurogenesis as a target for the treatment of mental illness: a critical evaluation. Neuropharmacology 58, 884-893 (2011).
157. Bramham, C. R. et al. The Arc of synaptic memory. Exp. Brain Res. 200, 125-140 (2010).
158. Minichiello, L. TrkB signalling pathways in LTP and learning. Nature Rev. Neurosci. 10, 850-860 (2009).
159. Peters, J., Dieppa-Perea, L. M., Melendez, L. M. & Quirk, G. J. Induction of fear extinction with hippocampal-infralimbic BDNF. Science 328, 1288-1290 (2010).
160. Wilkinson, L. S., Davies, W. & Isles, A. R. Genomic imprinting effects on brain development and function. Nature Rev. Neurosci. 8, 832-843 (2007). (Pubitemid 350006217)
161. Gregory, S. G. et al. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med. 7, 62 (2009).
162. Zhang, T. Y. & Meaney, M. Epigenetics and the environmental regulation of the genome and its function. Annu. Rev. Psychol. 61, 439-466 (2010).
163. Guidotti, A. et al. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology, 60, 1007-1016 (2010).
164. Kundakovic, M., Chen. Y., Guidotti, A. & Grayson, D. R. The reelin of GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol. Pharmacol. 75, 342-354 (2009).
165. Guan, J. S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55-60 (2009).
166. Koshibu, K., Grff, J. & Mansuy, I. M. Nuclear protein phosphate-1: an epigenetic regulator of fear memory and amygdala long-term potentiation. Neuroscience 173, 30-36 (2011).
167. Torrioli, M. et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am. J. Med. Genet. A 152A, 1420-1427 (2010).
168. Fischbach, S. J. & Carew, T. J. MiRNAs in memory processing. Neuron 63, 714-716 (2009).
169. Gao, J. et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 466, 1105-1109 (2010).
170. Hunsberger, J. G., Austin, D. R., Chen, G. & Manji, H. K. MiRNAs in mental health: from biological underpinnings to potential therapies. Neuromol. Med. 11, 173-182 (2009).
171. Kocerha, J. et al. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc. Natl Acad. Sci. USA 106, 3507-3512 (2009).
172. DeRubeis, R. J., Siegle, G. J. & Hollon, S. D. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nature Rev. Neurosci. 9, 788-796 (2008).
173. Medalia, A. & Choi, J. Cognitive remediation in schizophrenia. Neuropsychol. Rev. 19, 353-364 (2009).
174. Swerdlow, N. R. Are we studying and treating schizophrenia correctly? Schizophr. Res. 130, 1-10 (2011).
175. Cuijpers, P., van Staten, A., Hollon, S. D. & Andersson, G. The contribution of active medication to combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis. Acta Psychiatr. Scand. 19, 1-9 (2009).
176. Myers, K. M., Carlezon, W. A. & Davis, M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology 36, 274-293 (2011).
177. Modi, M. E. & Young, L. J. d-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. Biol. Psychiatry 70, 298-304 (2011).
178. Keefe, R. S. et al. Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr. Res. 125, 161-168 (2010).
179. Carter, C. S. & Barch, D. M. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr. Bull. 33, 1131-1137 (2007). (Pubitemid 47347921)
180. Heinrichs, R. W., Ammari, N., Miles, A. A. & McDermid Vaz, S. Cognitive performance and functional competence as predictors of community independence in schizophrenia. Schizophr. Bull. 36, 381-387 (2010).
181. Leifker, F. R., Patterson, T. L., Heaton, R. K. & Harvey, P. D. Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr. Bull. 37, 334-343 (2009).
182. Green, M. F., Kerns, S. R. & Heaton, R. K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 72, 45-51 (2004).
183. Hill, S. K., Reilly, J. L., Harris, M. S. H., Khine, T. & Sweeney, J. A. Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. Schizophr. Bull. 34, 494-506 (2008).
184. Luna, B., Velanova, K. & Geier, C. F. Development of eye-movement control. Brain Cogn. 68, 293-308 (2008).
185. Reilly, J. L., Lencer, R., Bishop, J., Keedy, S. & Sweeney, J. A. Pharmacological studies of eye movement control. Brain Cogn. 68, 415-435 (2008).
186. Noudoost, B. & Moore, T. Control of visual cortical signals by prefrontal dopamine. Nature 474, 375-379 (2011).
187. Keedy, S. K. et al. An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first episode schizophrenia. Psychiatry Res. 172, 16-23 (2009).
188. Sakkalis, V. Applied strategies towards EEG/MEG biomarker identification in clinical and cognitive research. Biomark. Med. 5, 93-105 (2011).
189. Braff, D. L. & Light, G. A. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology 174, 175-185 (2004).
190. Bodatsch, M. et al. Prediction of psychosis by mismatch negativity. Biol. Psychiatry 69, 959-966 (2011).
191. Lavoie, S. et al. Glutathione precursor, N-acetyl-cysteine, improved mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33, 2187-2199 (2008). (Pubitemid 351992093)
192. Fell, J. & Axmacher, N. The role of phase synchronisation in memory processes. Nature Rev. Neurosci. 12, 105-118 (2011).
193. Whittington, M. A., Cunningham, M. O., LeBeau, F. E. N., Racca, C. & Traub, R. D. Multiple origins of the cortical γ rhythm. Dev. Neurobiol. 71, 92-106 (2010).
194. Perry, A. et al. Intranasal oxytocin modulates EEG mu/alpha and beta rhythms during perception of biological motion. Psychoneuroendocrinology 35, 1446-1453 (2010).
195. Hali, S. D., Barnes, G. R., Furlong, P. L., Seri, S. & Hillebrand, A. Neuronal network pharmacodynamics of GABAergic modulation in the human cortex determined using pharmacomagnetoencephalography. Hum. Brain Mapp. 31, 581-594 (2010).
196. Higuchi, Y. et al. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophr. Res. 101, 320-330 (2008).
197. Murphy, S. E. & Mackay, C. E. Using MRI to measure drug action: caveats and new directions. J. Psychopharmacol. 25, 1168-1174 (2011).
198. Mu, Q. et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr. Res. 94, 332-341 (2007). (Pubitemid 47039290)
199. Lui, S. et al. Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. Arch. Gen. Psychiatry 67, 783-792 (2010).
200. Tregellas, J. R. et al. Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology 35, 938-942 (2010).
201. Riem, M. M. et al. Oxytocin modulates amygdala, insula, and inferior frontal gyrus responses to infant crying: a randomized controlled trial. Biol. Psychiatry 70, 291-297 (2011).
202. Garner, M., Zurowski, B. & Bachel, C. Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans. Proc. Natl Acad. Sci. USA 107, 9400-9405 (2010).
203. Broyd, S. J. et al. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci. Biobehav. Rev. 33, 279-296 (2009).
204. Sambataro, P. et al. Treatment with olanzapine is associated with modulation of the default mode network in patients with schizophrenia. Neuropsychopharmacology 35, 904-912 (2010).
205. Tregellas, J. R. et al. Effects of an α7-nicotinic agonist on default network activity in schizophrenia. Biol. Psychiatry 69, 7-11 (2011).
206. Minzenberg, M. J., Yoon, J. H. & Carter, C. S. Modafinil modulation of the default mode network. Psychopharmacology 215, 23-31 (2011).
207. Szulc, A. et al. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. Pharmacopsychiatry 44, 148-157 (2011).
208. Bustillo, J. R. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol. Psychiatry 69, 19-27 (2011).
209. Ertugrul, A. et al. The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: relationship with treatment response. Psychiatry Res. 174, 121-129 (2009).
210. Manganas, L. N. et al. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. Science 318, 980-985 (2007). (Pubitemid 350098995)
211. Vyas, N. S., Patel, N. H., Nijran, K. S., Al-Nahhas, A. & Puri, B. K. The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia. Expert Rev. Neurother. 11, 37-51 (2011).
212. Van Overwalle, F. & Baetens, K. Understanding others' actions and goals by mirror and mentalizing systems: a meta-analysis. Neuroimage 48, 564-584 (2009).
213. Young, L. J. & Wang, Z. The neurobiology of pair bonding. Nature Neurosci. 7, 1048-1054 (2004). (Pubitemid 41184443)
214. Hermann, E., Call, J., Hernandez-Lloreda, M. V., Hare, B. & Tomasello, M. Humans have evolved specialized skills to social cognition: the cultural intelligence hypothesis. Science 317, 1360-1366 (2007). (Pubitemid 47417471)
215. Carruthers, P. The cognitive functions of language. Behav. Brain Sci. 25, 657-674 (2002). (Pubitemid 37121638)
216. Nelson, B. & Rawlings, D. Relating schizotypy and personality to the phenomenology of creativity. Schizophr. Bull. 36, 388-399 (2010).
217. Hart, B. L., Hart, L. A. & Pinter-Wollman, N. Large brains and cognition: where do elephants fit in? Neurosci. Biobehav. Rev. 32, 86-98 (2008). (Pubitemid 350161897)
218. Premack, D. Human and animal cognition: continuity and discontinuity. Proc. Natl Acad. Sci. USA 104, 13861-13867 (2007). (Pubitemid 350003303)
219. McGraw, L. A. & Young, L. J. The prairie vole: an emerging model organism for understanding the social brain. Trends Neurosci. 33, 106-109 (2009).
220. Scattoni, M. L., Crawley, J. & Ricceri, L. Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders. Neurosci. Biobehav. Rev. 33, 508-515 (2009).
221. Arakawa, H., Blanchard, D. C., Arakawa, K., Dunlap, C. & Blanchard, R. J. Scent marking behavior as an odorant communication in mice. Neurosci. Biobehav. Rev. 32, 1236-1248 (2008).
222. Dunbar, R. I. The social role of touch in humans and primates: behavioural function and neurobiological mechanisms. Neurosci. Biobehav. Rev. 34, 260-268 (2010).
223. Buchanan, R. W. et al. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr. Bull. 37, 1209-1217 (2010).
224. Manahan-Vaughan, D., Widlfτrster, V. & Thomsen, C. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur. J. Neurosci. 28, 1342-1350 (2008).
225. Stefani, M. R. & Moghaddam, B. Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur. J. Pharmacol. 639, 26-32 (2010).
226. Ayala, J. E. et al. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 34, 2057-2071 (2009).
227. Zanto, F. P., Rubens, M. T., Thangavel, A. & Gazzaley, A. Causal role of the prefrontal cortex in top-down modulation of visual processing and working memory Nature Neurosci. 14, 656-662 (2011).
228. Belforte, J. E. et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neurosci. 13, 76-83 (2010).
229. Moreines, J. L., McClintock, S. M. & Holtzheimer, P. E. Neuropsychologic effects of neuromodulation technique for treatment-resistant depression: a review. Brain Stimul. 4, 17-27 (2010).
230. Matheson, S. L., Green, M. J., Loo, C. & Carr, V. J. Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial magnetic stimulation for schizophrenia: a systematic meta-review. Schizophr. Res. 118, 201-210 (2010).
231. Vanderhasselt, M. A., De Raedt, R., Baeken, C., Leyman, L. & D'Haanen, H. A single session of rTMS over the left dorsolateral prefrontal cortex influences attentional control in depressed patients. World J. Biol. Psychiatry 10, 34-42 (2009).
232. Barr, M. S. et al. Potentiation of γ oscillatory activity through repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex. Neuropsychopharmacology 34, 2359-2367 (2009).
233. Sokhadze, E. M. et al. Effects of low frequency repetitive transcranial magnetic stimulation (rTMS) on γ frequency oscillations and event-related potentials during processing of illusory figures in autism. J. Autism Dev. Disord. 39, 619-634 (2009).
234. Treffart, D. A. The savant syndrome: an extraordinary condition. A synopsis: past, present, future. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364, 1351-1358 (2009).
235. Cattaneo, Z., Pisoni, A. & Papagno, C. Transcranial direct current stimulation over Broca's region improves phonemic and semantic fluency in healthy individuals. Neuroscience 183, 64-70 (2011).
236. De Carvalho, M. R., Rozenthal, M. & Nardi, A. E. The fear circuitry in panic disorder and its modulation by cognitive-behaviour therapy interventions. World J. Biol. Psychiatry 11, 188-198 (2009).
237. Wykes, T., Huddy, V., Cellard, C., McGurk, S. R. & Czobor, P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 168, 472-485 (2011).
238. Naismith, S. L. Enhancing memory in late-life depression: the effects of a combined psychoeducation and cognitive training program. Am. J. Psychiatry 19, 240-248 (2011).
239. Alexander, G. E., DeLong, M. R. & Strick, P. L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9, 357-381 (1986). (Pubitemid 16055790)
240. Jung, R. E. & Haier, R. J. The parieto-frontal integration theory (P-FIT) of intelligence: converging neuroimaging evidence. Behav. Brain Sci. 30, 135-187 (2007).
241. Van Strien, N. M., Cappaert, N. L. M. & Witter, M. P. The anatomy of memory: an interactive overview of the parahippocampal-hippocampal network. Nature Rev. Neurosci. 10, 272-282 (2009).
242. Strick, P. L., Dum, R. P. & Fiez, J. A. Cerebellum and non-motor function. Annu. Rev. Neurosci. 32, 413-434 (2009).
243. Price, C. J. The anatomy of language: a review of 100 fMRI studies published in 2009. Ann. NY Acad. Sci. 1191, 62-88 (2010).
244. Saur, D. et al. Ventral and dorsal pathways for language. Proc. Natl Acad. Sci. USA 105, 18035-18040 (2008).
245. Fusar-Poli, P. et al. Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J. Psychiatry Neurosci. 34, 418-432 (2009).
246. Ishai, A., Schmidt, C. F. & Boesiger, P. Face perception is mediated by a distributed cortical network. Brain Res. Bull. 67, 87-93 (2005). (Pubitemid 41225321)
247. Cattaneo, L. & Rizzolatti, G. The mirror neuron system. Arch. Neurol. 66, 557-560 (2009).
248. Fadiga, L., Craighero, L. & D'Ausilio, A. Broca's area in language, action, and music. Ann. NY Acad. Sci. 1169, 448-458 (2009).
249. Doron, K. W., Funk, C. M. & Glickstein, M. Fronto-cerebellar circuits and eye movement control: a diffusion imaging tractography study on human cortico-pontine projections. Brain Res. 1307, 63-71 (2010).
250. Beaton, A. & Maria;n P. Language, cognition and the cerebellum: grappling with an enigma. Cortex 46, 811-820 (2010).
251. Watson, D. J. G., Marsden, M. A., Millan, M. J. & Fone, K. F. C. Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int. J. Neuropsychopharmacol. 18 Mar 2011 (doi:10.1017/S1461145711000435).
252. Loiseau F. & Millan M. J. Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D1 receptor agonists, but not of D2 antagonists. Eur. Neuropsychopharmacol. 19, 23-33 (2009).
253. Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R. & Cowart, M. D. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J. Pharmacol. Exp. Ther. 336, 38-46 (2011).
254. Sellin, A. K., Shad, M. & Tamminga, C. Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr. 13, 985-996 (2008).
255. McArthur, R. A., Gray, J. & Schreiber, R. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials. Curr. Opin. Invest. Drugs 11, 740-760 (2011).
256. Shimazaki, T., Kaku, A. & Chaki, S. d-serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology 20, 263-270 (2010).
257. Smith, S. M., Uslaner, J. M. & Hutson, P. H. The therapeutic potential of d-amino acid oxidase (DAAO) inhibitors. Open Med. Chem. J. 4, 3-9 (2010).
258. Labrie, V. et al. Genetic inactivation of d-amino acid oxidase enhances extinction and reversal learning in mice. Learn. Mem. 16, 28-37 (2009).
259. Roberts, B. M. et al. Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction. Behav. Brain Res. 212, 41-48 (2010).
260. O'Neill, M. J. & Dix, S. AMPA receptor potentiatiors as cognitive enhancers. IDrugs 10, 185-192 (2007). (Pubitemid 46438427)
261. Simonyi, A., Schachtman, T. R. & Christoffersen, G. R. J. Metabotropic glutamate receptor subtype 5 antagonism in learning and memory. Eur. J. Pharmacol. 639, 17-25 (2010).
262. Castner, S. A. et al. Reversal of ketamine-induced working memory impairments by the GABAAα2/3 agonist TPA023. Biol. Psychiatry 15, 998-1001 (2010).
263. Takahashi, R. N., Pamplona, F. A. & Prediger, R. D. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front. Biosci. 13, 2614-2632 (2008). (Pubitemid 351599708)
264. Wei, C. J. et al. Selective inactivation of adenosine A2A receptors in striatal neurons enhances working memory and reversal learning. Learn. Mem. 21, 459-474 (2011).
265. De Bruin, N. M. W. et al. SVL330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and social recognition tasks in rodents. Neurobiol. Learn. Mem. 217, 408-415 (2010).
266. Egashira, N., Mishima, K., Iwasaki, K., Oishi, R. & Fujiwara, M. New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions. J. Pharmacol. Sci. 109, 44-49 (2009).
267. Hongpaisan, J., Sun, M. K. & Alkon, D. L. PKCε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J. Neurosci. 12, 630-643 (2011).
268. Gozes, I. Microtubules, schizophrenia and cognitive behaviour: preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides 32, 428-431 (2010).